Roche's Itovebi shows significant benefit in overall survival for advanced breast cancer patients
From GlobeNewswire: 2025-01-28 01:00:00
Roche announced positive results from the INAVO120 study, showing a significant benefit in overall survival for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer. The Itovebi-based regimen doubled progression-free survival and is set to become a new standard of care. The study included 325 patients and is part of Roche’s efforts to improve survival rates for those with breast cancer. Itovebi, an oral targeted treatment, has shown potential for durable disease control. The FDA approved the Itovebi-based regimen in 2024, and Roche continues to explore additional studies in breast cancer and other tumor types. Updated overall survival (OS) results from the phase III INAVO120 study confirm the significant benefit of the ItovebiTM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer in the first-line setting. The regimen more than doubled progression-free survival in this patient population. Full OS results will be presented at an upcoming medical meeting. Roche is committed to sustainability and developing innovative medicines to help people live healthier lives. Genentech, a member of the Roche Group, is in the United States. For more information, visit www.roche.com. Contact Roche Global Media Relations or Investor Relations for further details. The updated overall survival (OS) results from the INAVO120 study confirm the significant benefit of the ItovebiTM-based regimen for advanced PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The primary analysis revealed a more than doubling of progression-free survival in this group. Full OS results will be presented at an upcoming medical meeting.
Read more at GlobeNewswire: Roche’s Itovebi demonstrated statistically significant and